What does primrose mrna — gross carrying value mean?

Represents the total original cost or acquisition value of financial royalty assets associated with the mRNA technology segment before any adjustments for impairment or allowances. This metric reflects the initial capital investment or valuation assigned to the royalty rights within this specific product category. It serves as a baseline for assessing the total asset exposure within the mRNA portfolio.

Ligand Pharmaceuticals (LGND) Primrose mRNA — Gross carrying value

Screener

Other product segments

Qarziba

$101.3M—

Similar metrics at other companies

GNTXOther — Gross carrying value

$38.4M—

SIRISiriusXM — Gross Carrying Value

$8.61B0.0%

GLTexas — Carrying value, gross, percent

15%-2.0pp

GLFlorida — Carrying value, gross, percent

19%0.0pp

GLAlabama — Carrying value, gross, percent

8%-1.0pp

SIRISirius XM — Gross Carrying Value

$570M0.0%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	June 30, 2026 / Gross carrying value(1)	June 30, 2026 / Allowance	June 30, 2026 / Net carrying value (1)	December 31, 2025 / Gross carrying value(1)	December 31, 2025 / Allowance	December 31, 2025 / Net carrying value(1)
Tolerance Therapeutics (Tzield®)	25,470	(99)	25,371	25,257	(98)	25,159
Ohtuvayre inventors	19,957	(179)	19,778	16,921	(151)	16,770
Elutia (CorMatrix)	6,062	(837)	5,225	6,607	(1,107)	5,500
AT220	4,442	(109)	4,333	5,132	(132)	5,000
Primrose mRNA	3,281	(98)	3,183	3,281	(98)	3,183
Zerion	2,640	(79)	2,561	—	—	—
Others	5,729	(212)	5,517	5,769	(214)	5,555
Total financial royalty assets, net	$209,699	$(2,489)	$207,210	$222,375	$(2,706)	$219,669

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's primrose mrna — gross carrying value?: Ligand Pharmaceuticals (LGND) reported primrose mrna — gross carrying value of $3.28M in Q2 2026.
What does primrose mrna — gross carrying value mean?: Represents the total original cost or acquisition value of financial royalty assets associated with the mRNA technology segment before any adjustments for impairment or allowances. This metric reflects the initial capital investment or valuation assigned to the royalty rights within this specific product category. It serves as a baseline for assessing the total asset exposure within the mRNA portfolio.